

ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation.

MAST, M.E., LEONG, A., KORREMAN, S.S., LEE, G., PROBST, Heidi <<http://orcid.org/0000-0003-0035-1946>>, SCHERER, P. and TSANG, Y.

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/32409/>

This document is the Accepted Version [AM]

Citation:

MAST, M.E., LEONG, A., KORREMAN, S.S., LEE, G., PROBST, Heidi, SCHERER, P. and TSANG, Y. (2023). ESTRO-ACROP guideline for positioning, immobilisation and setup verification for local and loco-regional photon breast cancer irradiation. *Technical Innovations & Patient Support in Radiation Oncology*, 28: 100219. [Article]

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

1 **ESTRO-ACROP guideline for positioning, immobilisation and set-up**
2 **verification for local and loco-regional photon breast cancer irradiation**

3
4 M.E. Mast (PhD)¹, A. Leong^{2,3}, S.S. Korreman (PhD)^{4,5,6}, G. Lee^{7,8}, H. Probst (PhD)⁹, P. Scherer¹⁰, Y.
5 Tsang (PhD)⁷

6 ¹Department of Radiation Oncology, Haaglanden Medical Center, Leidschendam, the
7 Netherlands

8 ²Department of Radiation Therapy, University of Otago, Wellington, New Zealand

9 ³Bowen Icon Cancer Centre, Wellington, New Zealand

10 ⁴Department of Clinical Medicine, Aarhus University

11 ⁵Department of Oncology, Aarhus University Hospital

12 ⁶Danish Center for Particle Therapy, Aarhus University Hospital

13 ⁷Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada

14 ⁸Department of Radiation Oncology, University of Toronto, Toronto, Canada

15 ⁹Sheffield Hallam University, Sheffield, United Kingdom

16 ¹⁰Department of Radiotherapy and Radio-Oncology, LKH Salzburg, Paracelsus Medical
17 University Clinics, Salzburg, Austria

18
19
20 Aim: review of available evidence in conjunction with expert opinion to form recommended
21 guidelines on positioning and set up verification for breast cancer irradiation

22 Wordcount: 7218

23

24 **Summary of recommendations**

Topic	Recommendations
Positioning	<ul style="list-style-type: none"> • For most breast cancer treatments supine is the standard position. For patients with larger breasts or patients that require a higher degree of lung sparing, prone can be considered if the equipment and expertise are available. • Both arms up are considered more stable; one arm up may be considered for patients that cannot tolerate both arms up. • When using supine positioning, both flat and elevated board positions are acceptable provided collision risks are managed and the patient is appropriately stabilised.
Immobilisation	<ul style="list-style-type: none"> • There is insufficient evidence to support the adoption of any specific immobilisation device of the breast. The pro and cons of specific immobilisation devices must be weighed carefully and evaluated by the local department prior to clinical implementation.
Setup	<ul style="list-style-type: none"> • In the absence of surface guided imaging, the use of skin marking is required. • The available options for skin marking should be discussed taking into account long-term patient experience and patient preference.
Position Verification	<ul style="list-style-type: none"> • Daily 2D-2D or 3D online position verification should be used where feasible. • 2D online/offline position verification is appropriate with consideration of limitations. • Image matching should consider bony anatomy as well as soft tissue displacement/deformation. • SGRT should not replace standard image-guidance without local validation and particular caution to partial-breast/integrated-boost treatments.

25

26 **Introduction**

27 Breast cancer is the second most common malignancy worldwide, representing 11.9% of all
 28 diagnoses[1]. A more favourable survival from breast cancer is typically observed in developed regions
 29 along with a higher incidence[1]. The meta-analysis of the Early Breast Cancer Trialists' Collaborative
 30 Group (EBCTCG) showed that breast cancer recurrences were decreased by 50% and breast cancer
 31 death after 15 years by about 15% when using radiotherapy after breast conserving surgery in
 32 patients with breast cancer[2]. More frequently, hypofractionation schemes are used. Several
 33 randomised studies reported comparable local control rates and breast cosmesis for the 3-week
 34 hypofractionation schedule (40Gy in 15 fractions) compared to 5-weeks of conventionally fractionated
 35 treatment (50Gy in 25 fractions)[3–5]. According to Whelan et al., the hypofractionation schedule is
 36 more convenient for patients and less costly, which may result in an increase in the number of women
 37 receiving whole breast irradiation after breast conserving surgery[5].

38 With improved survival outcomes, the need to further minimise side effects is of paramount
39 importance. While radiation treatment plans are carefully designed to spare normal tissue, accuracy
40 of treatment delivery is fundamental to ensure that this sparing is achieved for each individual
41 fraction. This accuracy of treatment delivery in turn relies upon the stability and reproducibility of
42 patient positioning in combination with robust set-up verification and motion management.

43

44 In many countries the five fractions schedule was introduced more rapidly due to COVID-19, based on
45 the results of the FAST and the FAST-Forward trials[6–11]. The speed of adoption has not given us
46 time to reflect on this, but these hypofractionation schemes demand an increased awareness of daily
47 variations in treatment accuracy and precision due to the higher dose per fraction. In the literature, a
48 wide variety of studies concerning improvement in breast cancer positioning and position verification
49 can be found. However, an overview exploring how best to meet these requirements of accuracy is
50 lacking. This guideline was developed to analyse and discuss the positioning, immobilisation, set-up
51 and position verification strategies used for local and loco-regional photon breast cancer irradiation
52 after lumpectomy or mastectomy. It aims to offer practical recommendations to improve the accuracy
53 of breast cancer radiation treatment, and to inform opportunities for future research priorities. This
54 guideline is presented in sections where the authors have distilled the literature to provide
55 recommendations. Furthermore, the authors have included additional considerations in areas for
56 which there is only a limited level of evidence.

57

58 **Materials and methods**

59 For the literature review the databases of PubMed, Cochrane and Google Scholar were used. The
60 search terms were defined, and the search was performed in January 2019, see Supplementary Table
61 1 for all search terms. This resulted in 431 studies found in PubMed and Cochrane, and 326 studies on
62 Google Scholar. After removing duplicates, one author selected relevant references based on their
63 titles, the selection was verified by a second author. Pairs of authors were assigned to the following
64 topics: “positioning”, “immobilisation”, “set-up” and “position verification” for further review. Each
65 pair selected the references for full text review based on the abstracts. If authors could not reach
66 consensus on inclusion from initial abstract review, then the full paper was reviewed for a more
67 comprehensive assessment. If consensus could still not be reached between the pairs of authors, then
68 additional input from the wider author group was sought. Studies in English, German and Dutch were
69 included. Each pair read the selected manuscripts, assessed them using risk of bias tools for
70 randomised or non-randomised studies [12,13] and completed evidence tables for their respective
71 topic (Supplementary Tables 2-5). Following group review of the evidence tables, the guideline was

72 written, and recommendations were proposed where appropriately supported by evidence. Aspects
73 of practice considered highly relevant for practitioners but unable to be recommended due to the
74 limitations of research were included as ‘considerations’. Literature published after January 2019 that
75 was considered of importance for this guideline was additionally included. The literature review was
76 complemented with the experiences and the specific knowledge of the globally distributed authors of
77 this guideline. For a comprehensive overview of the contributions of the authors to this guideline we
78 refer to the contribution table.

79 Two specific points are of importance. Firstly, the literature search term “Breathing” was initially
80 included. It was subsequently decided that literature regarding the effect of respiratory motion on the
81 radiation treatment plan was excluded since this is outside the scope of this guideline describing the
82 end-to-end procedure of positioning the patient. Secondly, numeric values for setup error are
83 reported where available. Studies that calculated relative increases or reductions in calculated
84 Planning Target Volume (PTV) margins (considering institution's specific equipment, workflow and
85 patient population) were acknowledged as such, however advice on specific PTV margins was beyond
86 the scope of this guideline and not discussed. Finally, during the compilation of this guideline new
87 immobilisation devices are in development and early studies have been performed to test these.
88 These early pilot/feasibility studies have not been included in this guideline.

89

90 **Results, Recommendations and Considerations**

91 **1.1 Positioning**

92 **1.1.1 Supine vs prone: whole breast irradiation**

93 From the literature search (Supplementary Table 2), it was evident that in 90% of the studies patients
94 are positioned supine. Two randomised control trials (RCT) were carried out comparing prone with
95 supine treatment. Mulliez et al. executed a RCT to evaluate the acute skin toxicity (dermatitis, pruritus,
96 and pain). The latter was evaluated before treatment, weekly during irradiation and 1–2 weeks after
97 completion of the treatment by a radiation nurse and a radiation oncologist. Prone treatment in
98 patients with larger breasts appears to reduce desquamation, dermatitis, edema and pain significantly
99 compared to supine treatment[14]. In the second RCT Kirby et al. included 26 patients in a cross-over
100 trial; all were imaged in supine and prone position. The investigators found greater set-up errors in
101 the prone position, resulting in a larger Clinical Target Volume (CTV) –PTV margin (for chest-wall and
102 clip-based translational errors in 3-dimensions: systematic errors: 1.3–1.9mm (supine); 3.1–4.3mm
103 (prone); random errors: 2.6–3.2mm (supine); 3.8–5.4mm (prone)). Further optimizing the prone
104 positioning and increasing experience of the staff might be of influence to reduce these larger
105 positioning deviations[15]. A breast-volume threshold for prone radiotherapy was not defined,

106 although both RCTs included patients with breast cup size $\geq C$. Several authors tried to define
107 predictors for defining the most optimal position, supine or prone treatment. Unfortunately, a widely
108 applicable predictor that predefines the optimal individual treatment position cannot be derived from
109 these studies, since no overlapping predictor has been found[16–20]. Furthermore, the literature
110 search included a large variety of cohort studies with various study objectives, these were assessed
111 with a focus on comparing supine and prone treatment positions. From this it can be concluded that
112 when the heart dose is the most important factor, supine Deep Inspiration Breath-hold (DIBH)
113 treatment appears to be the best option. However, when lung dose is of importance as well, the prone
114 treatment can be an option as the breast tissue falls anteriorly and away from the lung [17,18,21,22].
115 The RCT of Bartlett et al., comparing supine voluntary breath-hold (VBH) in left-sided breast cancer
116 with prone treatment, showed that supine VBH provided superior cardiac sparing and reproducibility
117 than a free-breathing prone position in larger-breasted women (CTV volume $> 1029 \text{ cm}^3$)[23]. Even in
118 free-breathing, Kahán et al. reported that 1 in 5 women had higher dose to cardiac structures when
119 positioned prone compared to supine[19]. In two systematic reviews more specific information
120 concerning the heart and lung dose was described extensively[24,25].

121 Other studies focused on different variables when performing prone breast cancer treatment.
122 Mitchell et al. states that there is a need for a larger CTV-PTV margin when treating patients in the
123 prone position imaged with an EPID device in cine mode. The image analysis was therefore limited to
124 in plane movement missing lateral or rotational errors[26]. Buijsen et al. showed that for patients with
125 larger breasts the dose homogeneity can be improved in prone position, although a lower PTV
126 coverage was reported[27]. A meta-analysis published in 2021 compared prone and supine treatment
127 in free breathing, in patients with breast cancer after breast-conserving surgery without metastasis,
128 suggesting that prone resulted in better heart sparing. Due to the low numbers of studies, the prone
129 versus supine treatment in breath-hold was not compared[28].

130 Concerning the outcome of the prone treatment from the RCT performed by Vakaet et al., it appeared
131 that cosmesis (non-blinded analysis using the BCCT.core classification[29]) was good or excellent in
132 92% and 75% of patients who used prone and supine positioning, respectively. The physician-assessed
133 toxicity at 5 years was not different except for pigmentation changes measured on the LENT-SOMA
134 scale, the 5-year overall survival was equal in both groups[30]. A better cosmesis was obtained
135 because of a significantly better homogeneity of the isodoses in the breast in the prone position
136 compared to supine[14]. A good cosmesis was confirmed by other studies as well. Etin-Osa et al.
137 reported that with a median follow-up time of five years, hypo-fractionated breast RT with a
138 simultaneous integrated boost in the prone position resulted in excellent cosmesis (patient reported)
139 and normal tissue sparing. Longer follow-up is needed to confirm the efficacy and safety of this

140 approach[31]. Based on the physician-assessed Harvard scale of cosmetic outcome[32] Bergom et al.
141 found that 86% of the patients with breast volumes $>1200\text{cm}^3$ reported good to excellent
142 cosmesis[33]. Finally, according to Yu et al. and Kahan et al.[19,21] the prone position puts higher
143 demands on staff and patient compliance. Huppert et al. described that pain from the neck and spine
144 muscles was a common complaint. They stated that caution should be taken in women with history
145 of neck injury or disk problems[34].

146

147 **1.1.2 Supine vs prone: loco-regional treatment**

148 For loco-regional treatment, 11 articles were reviewed. Csenki et al. performed the largest study, they
149 compared prone and supine position in free breathing in 100 patients and showed that in most cases
150 the intended doses to axillary levels I–III and the internal mammary (IM) lymph nodes were
151 inadequate, regardless of the treatment position. In this treatment planning study the nodal doses
152 were significantly lower in the prone than in the supine position[35]. Alonso-Basanta et al. confirmed
153 the latter, they compared prone or supine positioning in 20 patients for nodal treatment. On average,
154 the mean dose to the nodal region levels I-III was 50% less in the prone as compared with the supine
155 position[36]. However, in 2012 they reported that IMRT improved the target coverage for both
156 positions[37]. Sethi et al. also advised that a larger cut-out in the prone breast board is needed to
157 allow access to both breast and nodal volumes[37].

158

159 Deseyne et al. and Speleers et al. from Ghent University Hospital performed two treatment planning
160 studies in small cohorts (5 and 6 patients respectively) and reported good target coverage (breast and
161 nodal volumes) and less dose in the organs at risk when prone position was compared to supine
162 treatment in free breathing[38,39]. Deseyne et al. found significantly reduced doses for ipsilateral
163 lung, thyroid, contralateral breast, contralateral lung and oesophagus in prone treatment[38].
164 Speleers et al. described that mean doses to organs-at-risk were generally lower for prone crawl than
165 for supine positions and for proton than for photon plans. Dose in the left anterior descending
166 coronary artery, lungs, ipsilateral lung and thyroid was lower for prone photon and proton
167 treatment[39]. Recently they described the dosimetric effect of DIBH in prone nodal treatment in 31
168 patients. They found that also for loco-regional treatment, the combination of prone positioning and
169 DIBH will allow for achieving substantially lower heart (an average reduction of 2Gy when applying
170 DIBH) and lung doses (left mean lung dose was decreased by 13% when using DIBH in photon therapy
171 and 21% in proton therapy) than supine or prone in shallow breathing and supine DIBH, in both photon
172 and proton treatments[40,41]. From an earlier study, it appeared that the patients experienced
173 discomfort in the prone position caused by bilateral arm elevation. Therefore, the Belgian team

174 developed a dedicated breast board in which the patients lie in a prone crawl position. The ipsilateral
175 arm alongside the body was reported to be more comfortable, especially after axillary node
176 dissection[42].

177 Shin et al. described the prone position of radiation treatment after mastectomy[43]. The outcome
178 was promising. Prone hypofractionated breast, chest wall, and nodal radiation therapy was safe and
179 well-tolerated in this study. 4% of the patients were rescanned in supine position to better spare the
180 heart. None of the patients experienced grade 2 acute skin toxicity; concerning late toxicity 1 grade 3
181 breast retraction and no grade 2 was found. Although the initial pattern of local and regional control
182 is encouraging, longer follow-up is warranted for efficacy and late toxicity assessment[43].

183

184 **1.1.3 Lateral decubitus position**

185 Another position variation is the lateral decubitus position. The group of institute Curie in Paris
186 described their experience in large groups of around 1500 patients, in the period 1996-2014. They
187 found a large dose reduction in the heart, ipsilateral lung and contralateral breast[44–46]. Moreover,
188 they noted that the lateral decubitus position was well-tolerated and showed excellent dosimetric and
189 clinical results. The cosmetic outcome was good or excellent in 81-85% of the patients[46,47].
190 Davidson et al. assessed the set-up accuracy of electron boosts delivered in the lateral decubitus
191 position. The authors reported larger positioning deviations than expected in the supine position,
192 including seven of 33 patients that demonstrated average table shifts of 2cm or more[48]. Bronsart et
193 al. addressed this as well. They stated that the increased complexity was a disadvantage of this
194 positioning method, and advised for an experienced team, including a dedicated patient board[46].

195

196 **Recommendations**

- 197 • Based on the literature and the current equipment we recommend the supine position as the
198 standard for most treatments, see the recommendations when prone positioning is advised
199 below. This is also in line with the commentary of Haffty: “Supine is the widely accepted norm,
200 and simplest approach”[49].
- 201 • Supine is advantageous when combined with Surface Guided Radiotherapy (SGRT) since the
202 breast is visible for the systems.
- 203 • It must be noted that prone and supine comparison studies are mostly performed more than
204 10 years ago, therefore research could be of added value considering technical improvements
205 in radiotherapy treatment.

- 206 • Prone holds value for improving dose homogeneity, which might result in better cosmesis,
207 and reducing lung and skin-fold dose but can be challenging to implement and a dedicated
208 team is needed.
- 209 • For patients with larger breasts or patients that require a higher degree of lung sparing, prone
210 may be considered if the equipment and expertise are available, and the patient can tolerate
211 the position.
- 212 • Unfortunately, a widely applicable predictor that predefines the optimal individual treatment
213 position cannot be derived from these studies, since no overlapping predictor has been found.
- 214 • For more experienced departments treatment in prone position for loco-regional radiation
215 treatment and partial breast irradiation is achievable; outcomes reported are promising,
216 however research is needed to confirm the findings up until now.
- 217 • Concerning the variation in nodal dose coverage in the prone position compared to the supine
218 position that are reported in the literature it is recommended to perform comparison studies
219 with modern radiation therapy techniques in the future. The suitability of specific prone
220 positioning devices for treatments with nodal involvement must be carefully evaluated by
221 individual departments based on their local planning technique.

222 **Considerations**

- 223 • The lateral decubitus position has been shown to be an option in a centre with considerable
224 expertise in adopting this position. Reproducibility may be an issue and it is not certain that
225 nodal irradiation could be delivered in this position. This treatment position is more complex
226 and demands a dedicated team. Further research is needed including data regarding how well
227 this position is maintained across different breast volumes.
- 228 • Several studies describe the outcome of Accelerated Partial Breast Irradiation (APBI) in prone
229 position; however, no comparison studies (supine versus prone) have been performed for
230 APBI.
- 231 • In addition to stability and comfort, patient experience should also be considered from the
232 perspective of patient preference when evaluating patient position. While there is a lack of
233 evidence in this area, departments are encouraged to engage with patients when evaluating
234 new patient positioning workflows.

235 **1.2 Supine positioning one arm up vs both arms up**

236 Goldsworthy et al. randomised 50 patients between bilateral arm and unilateral arm abduction. They
237 concluded that with bilateral arm abduction a reduction in the systematic error and inter-patient
238 variability could be achieved. Bilateral arm abduction was a more stable and reproducible position

239 (significantly lower translational displacement: 3.1 mm versus 5.3 mm; and population systematic
240 errors 1.9mm versus 2.7mm)[50]. In addition, Graham et al. simulated thirty patients in a randomised
241 trial in both an armrest and a vacuum bag. The patients were also randomised between treatment in
242 one of the two devices. Overall, patient comfort significantly favoured the use of the armrest, although
243 both were acceptable. Treatment times and stability of the setups were not significantly different[51].
244 Xiang et al. positioned patients on a supine breast bracket, using an immobilisation mould, with both
245 arms abducted and hands either holding a single-pole or double-pole position (both hands holding
246 separate poles). The single-pole position was perceived by patients as being more comfortable and
247 reduced heart doses, when compared to the double-pole position[52]. However, the results might be
248 different in a cohort of patients not using moulds. Saito et al. scanned patients with breast cancer in
249 two arm positions: ipsilateral arm at 90 degrees to the body axis; and both arms above the head. When
250 the arm position changed to two arms above the head, level I lymph nodes moved anteriorly and
251 medially and level II and III axillary nodes moved posteriorly and medially, resulting in under and
252 overdosage of the target volumes. To note the dose distribution to each lymph node level was
253 determined using historically designed fields in each arm position. A limitation was that the findings
254 were based on anatomic landmarks instead of delineated lymph node levels[53]. Finally, Kapanen et
255 al. retrospectively studied two arm positions using: the house-made rod-hold (RH) or the standard
256 wrist-hold (WH). With the RH, the irradiated volumes of the humeral head were approximately 2 times
257 larger than with the WH. Daily image guidance was recommended because of large random position
258 errors obtained for the arm position with both devices[54].

259

260 **Recommendations**

- 261 • Both arms up are considered more stable from one randomised study, in this study
262 significantly lower translational displacements were found.
- 263 • Other cohort studies conclude that the single arm position and armrest are experienced as
264 more comfortable by patients. Therefore, one arm up may be considered for patients that
265 cannot tolerate both arms up.
- 266 • Goldsworthy et al. described the contralateral arm position as “abducted to the side of the
267 patient or across her waist”[50].

268 **Considerations**

- 269 • According to the experiences of the authors, with both arms up the patient is lying more
270 symmetrically, which could be helpful in positioning the patient.

- 271 • Of importance is that the position of the arm can influence the localisation of nodal volumes.
272 Daily image guidance may be necessary to verify the arm position.
- 273 • To note, centres might avoid a both arms up technique due to potential collision with the CT
274 bore or the linac gantry. It might be of value to investigate whether the position of the patient
275 can be adapted, e.g., treat the patient in an inclined or flat position.
- 276 • It is important to note that none of the abovementioned studies include the patient's Body
277 Mass Index (BMI), therefore it is unclear whether findings are applicable to patients of larger
278 body habitus and BMI.
- 279 • Regarding the ability of the patient to adequately mobilise the shoulders, several RCTs report
280 that physiotherapy improves shoulder function after surgery[55–59]. The coordination of
281 radiotherapy and physiotherapy after the operation can be challenging in some departments,
282 as it is resource intensive, and physiotherapy may not be readily available.

283 **1.3. Flat vs elevated**

284 As described in paragraph 1.1.1 and 1.1.2. patients are most often positioned in supine position lying
285 flat or on an inclined positioning device at a fixed angle. In a cohort study, 10 patients with left-sided
286 breast cancer were CT scanned in the flat position and the elevated position. The patients were
287 treated with whole breast irradiation, making use of two tangential fields. It was found that the PTV
288 moves cranially with the patient lying in the flat position. The dose outside the PTV in the nodal area
289 was 30Gy in the elevated position vs 23Gy in the flat position ($p < 0.01$)[60]. However, flat positioning
290 allows greater gantry clearance for a range of imaging and treatment modalities. An elevated position
291 has been used historically for improving conformity of conventional planning techniques, which is
292 generally no longer a consideration. When using an inclined position Jain et al. showed that a foot
293 support is of importance to avoid the patient shifting inferiorly during the treatment process[61].

294

295 **Recommendations**

- 296 • Based on clinical experiences both flat and elevated positions are acceptable provided
297 collision risks are managed, and the patient is appropriately stabilised and comfortable.
- 298 • It could be of benefit to some patients with larger body habitus to be slightly inclined/elevated
299 to decrease cranial target movement and decrease the irradiation of additional healthy tissue.

300 **Considerations**

- 301 • While lacking formal evidence, anecdotally the authors strongly advise the use of positioning
302 aids, e.g., supine breast boards, which can be indexed to both the treatment couch and skin
303 reference marks for efficient and accurate patient positioning.

- As far as the authors are aware, there is a lack of studies directly comparing OAR dose, reproducibility, or comfort between flat or elevated positions.

2. Breast immobilisation

In addition to general patient positioning considerations discussed in the section prior, more specialised immobilisation devices can be employed with the aim of stabilising the breast in a position more advantageous for treatment planning. A total of 16 articles were reviewed in the topic of breast RT immobilisation device and the 7 articles included had low or moderate risk of bias, Supplementary Table 3.

The most common methods of breast immobilisation within the reviewed papers related to the use of an external thermoplastic mould or treatment bra in the supine position. Arenas et al. examined the impact of a plastic treatment bra on plan dosimetry in 12 patients with early-stage breast cancer with large (D cup) or pendulous breasts. Plans generated for each patient with and without the treatment bra demonstrated a significant reduction in PTV and irradiated (V95) volumes with bra use. Mean heart and lung dose were significantly reduced by 66.7% (1.4 vs 4.9Gy) and 65.6% (3 vs 8Gy) with bra use, respectively. Of note, this study was performed under free-breathing therefore the benefit of a treatment bra to heart-sparing together with DIBH cannot be confirmed. Conversely, phantom measurements within the study indicated that skin dose increased with bra use by a factor of approximately 1.5[62].

Shi et al. reported similar findings from a retrospective cohort study comparing patients immobilised with an upper body thermoplastic mould to a control group standardly positioned on an elevated wing board. Significant reductions in heart and lung dose were found with the use of this immobilisation mould, at no compromise to PTV coverage. Though skin dose was not assessed, the descriptive analysis reported erythema in 9% more patients treated with a thermoplastic mould than in the group treated without a mould. Of the patients treated with a thermoplastic mould, 80% of the proportion reported pain and skin tenderness at 3-months post-radiotherapy, 9% had grade 3 symptoms[63]. A phantom study by Kelly et al. investigating skin dose from varying thicknesses of breast thermoplastic moulds and reported dose increases of up to 62%[64].

Breast setup reproducibility with immobilisation was explored in a sample of 16 patients, eight of whom had a thermoplastic mould created from the neck to the whole breast. However, no improvement in position accuracy was found based on daily Megavolt CT (MVCT) matching[65].

Kawamura et al. evaluated the setup reproducibility of 35 patients with pre-operative breast cancer in the prone position with and without a modified fabric bra. Repeated MRI scans were used to track both external breast contour and tumour location. Increased stability in tumour location was found with bra use, though differences were on average <1mm[66].

338 In addition to treatment bras and thermoplastic moulds, several studies described the use of more
339 specialised devices for other radiation treatment technologies. A pre-clinical feasibility study by
340 Arimura et al. reported the development of a hybrid breast immobilisation system for proton therapy.
341 Combining whole body immobilisation with a 3D-printed breast cup has been shown to achieve a high
342 level of breast stability, including mitigation of respiratory motion in preliminary results[67]. In a
343 similarly specialised context, Snider et al. carried out a planning study of 15 patients testing a breast-
344 specific stereotactic treatment machine, the GammaPod. Patients were positioned in the prone
345 position on a custom treatment couch with a vacuum-assisted breast cup, which the authors report
346 as validated for delivering a treatment with a PTV margin of 3mm[68]. Both technologies are of
347 interest for continued research but are not yet applicable in general clinical contexts.

348

349 **Recommendations**

- 350 • There is currently insufficient evidence to support the widespread adoption of any specific
351 type of immobilisation device of the breast.
- 352 • Treatment bras or thermoplastic moulds may be beneficial for selected patients with
353 large/pendulous breasts in stabilising breast tissue in a position that enables more effective
354 organs at risk (OARs) sparing. Studies using moulds in prone treatment or comparing the use
355 of moulds in supine with prone treatment have not been performed yet in patients with large
356 breasts.
- 357 • The impact of any immobilisation device on skin dose and subsequent risk of increased toxicity
358 must be carefully evaluated by the local department prior to clinical implementation, and
359 closely monitored thereafter.

360 **Considerations**

- 361 • Breast immobilisation methods can be complex to reproduce during treatment if they are not
362 implemented with extensive training and clear documentation, i.e., documentation for
363 application and troubleshooting.
- 364 • While some methods of immobilisation can give patients more dignity by covering their
365 breasts, immobilisation devices that require the treatment staff to manipulate or position the
366 patient's breast within the immobilisation device itself can diminish the patient's experience
367 and make the procedure less dignified and may cause additional discomfort if the patient has
368 developed radiation dermatitis.

- When applying a breast immobilisation device together with SGRT, in-house testing should be undertaken to identify how positioning of the device and its impact on the patient surface is managed within the SGRT workflow.

372

373 **3. Setup**

374 A total of sixteen articles were reviewed in relation to setup for breast cancer radiotherapy
375 (Supplementary Table 4). Only studies that included a comparator within the context of the setup
376 process were included, resulting in four articles related to treatments delivered in the supine position.
377 Setup here is defined as the process of reproducing the patient’s planned position prior to each
378 treatment fraction. This is distinguished from initial patient positioning established at CT simulation
379 (discussed in the previous section), and the verification of patient setup during treatment (discussed
380 in the following section). During CT, simulation reference marks are standardly placed on the patient’s
381 skin surface which may be tattoos or non-permanent skin marks. This was studied in an RCT (176 vs
382 166 patients) to investigate the treatment accuracy of both types of skin marks[69]. Based on weekly
383 portal imaging, no significant difference in random and systematic errors could be identified between
384 the two groups. Additional to considerations regarding setup accuracy, the SuPPORT 4All study
385 reported that permanent tattoos may impact patients’ wellbeing[70]. Petillion et al.[71] found that
386 the skin mobility makes the lateral skin marks less reliable for anteroposterior patient setup. Setting
387 a calculated vertical couch position was seen to reduce random setup error in the anteroposterior
388 direction from 4.6mm to 2.2mm. Furthermore, Gonzalez et al. recently showed that SGRT resulted in
389 a significant increase in the accuracy of surgical clip localisation within the breast compared to skin
390 marker-based setup[72]. SGRT is further discussed in the position verification section of this guideline,
391 and its comparability to other IGRT modalities further supports its potential to replace the role of skin
392 marks.

393


394 **Recommendations**

395 Given the limited published data available, there is similarly limited evidence to guide practice
396 recommendations. In general, skin marks are needed to set-up the patient before performing a
397 position verification procedure. In the absence of relevant evidence, the guideline authors [70] advise
398 the following configuration of skin marks, Figure 1:

- Caudal: one skin mark at patient sagittal mid-line;
- Lateral: two points at each side of the patient halfway the chest since these are stable points.

401

402



403

404

Figure 1: Configuration of the skin marks for patient setup

405

406 **Considerations**

- 407 • Setting a calculated couch vertical position rather than shifting from lateral skin mark height
408 (for offline position verification) could be helpful to improve setup accuracy.
- 409 • Temporary skin marks may be an alternative to permanent tattoos with a lesser impact on
410 patient well-being[70].
- 411 • SGRT may improve setup accuracy and enable the omission of skin marks entirely, though this
412 must be validated in the context of a department's local workflow.

413

414 **4. Position verification**

415 Position verification encompasses the imaging modality utilised, the frequency with which the
416 modality is applied, and the matching structures that are prioritised when evaluating setup errors and
417 applying corrections. For the purposes of this guideline, data relating to intrafractional position
418 verification, and the impact of respiratory motion were excluded.

419 Fifty-two studies were identified as relating to position verification, Supplementary Table 5. Table 1
420 shows the distribution of studies by imaging modality utilised. Importantly, 39 studies (75%) included
421 only a single imaging modality. Such studies were considered to be at high risk of bias and of limited
422 value when considering the value of one imaging modality over another as variations in patient
423 positioning and image matching practice cannot be readily accounted for. Of the 13 studies comparing
424 two or more imaging modalities, seven[73–79] related to the validation of surface-guided RT (SGRT),
425 with the remaining six[61,80–84] involving some combination of 2D, 2D-2D and 3D modalities. A
426 similarly limited number of studies directly evaluated different imaging frequencies or matching
427 processes.

Imaging modality	Number of studies (%)*	References
2D (e.g., kV, MV)	19 (37%)	[26,61,75,76,81,82,84–96]
2D-2D (e.g., kV-kV, MV-kV)	18 (35%)	[77,79–81,83,84,86,97–107]
3D (e.g., CBCT, MVCT)	17 (33%)	[61,73,74,78,80,82–84,108–116]
SGRT	8 (15%)	[73–79,117]
Other (e.g., ultrasound, MRI)	4 (8%)	[118–121]
Total	52 (100%)	

Table 1: The distribution of studies by imaging modality.

*The combined modality numbers exceed the total number of studies assessed due to 13 studies including multiple imaging modalities.

428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455

2D imaging has been a long-established approach to breast position verification, based primarily on MV portal imaging of treatment field(s) and evaluation of the chest wall and anterior breast contour. A wide range of 2D imaging frequencies were reported across the selected studies from weekly to daily. In the absence of daily imaging, random setup error cannot be accounted for, though systematic errors can be somewhat mitigated using action-level protocols[122,123]. Importantly, systematic errors require comparatively larger PTV margin expansions to reduce the risk of geometric miss of the tumour volume over the course of treatment[124]. Among the 19 2D imaging studies, 12 included no comparator modality, and reported systematic and random errors ranged from 1.5-23.4mm and 1.5-7.6mm, respectively[26,85–96]. While these values are primarily indicative of setup reproducibility between studies, they also highlight the need to validate setup errors locally to ensure that the accuracy achieved by departmental workflows is adequate for the PTV margins applied.

2D imaging is limited in that ‘out of plane’ (i.e., perpendicular to the image acquired) setup errors cannot be assessed. Jain et al.[61] evaluated the setup errors of 10 patients using post-treatment Cone Beam CT (CBCT) following initial 2D imaging. All patients were found to have systematic errors exceeding 5mm in at least one direction, though this was most frequently observed in the lateral plane. Plans were recalculated based on these errors and demonstrated reduced target volume coverage and homogeneity. Similarly, Topolnjak et al.[82] compared CBCT and portal images for 20 patients and found 2D imaging to underestimate both systematic and random errors.

2D-2D imaging enables localisation of the patient in all three planes through the acquisition of two images typically acquired at orthogonal angles. Petillion et al.[107] compared two methods of orthogonal imaging at cardinal (i.e., 0°, 90°, 180°, 270°) and non-cardinal angles (derived from the tangential treatment field). The non-cardinal technique was found to have significantly reduced residual error based on intrafractional 2D imaging and would enable whole-breast PTV margins to be reduced by 3-4mm. 2D-2D residual errors have been similarly assessed but based on image match

456 prioritisation by Laaksooma et al.[100]. Using cardinal imaging angles, matching to a combination of
457 the sternum, ribs and vertebrae was found to be optimal, while the vertebrae alone were the least
458 accurate. A PTV margin reduction of 1.2mm in the posterior tangential plane was calculated to be
459 feasible from the reduction in residual error. Studies involving CBCT following initial 2D-2D match have
460 shown residual errors of 3-5mm[83] and the need for additional PTV margins of approximately
461 2mm[80].

462 3D imaging, most commonly in the form of CBCT, offers the benefit of soft tissue visualisation
463 throughout all three planes of the patient. As reported above, studies have indicated the value of 3D
464 imaging in identifying residual error from 2D and 2D-2D imaging modalities, further enabling more
465 accurate validation of PTV margins. Such data is however complicated by the range of structures that
466 can be used to determine the 'ideal' matched position of 3D images. Studies involving partial-breast
467 irradiation often focus on the localisation of surgical clips[80] or the surgical bed[83], which may not
468 be representative of the wider target volume treated in whole-breast, or locoregional, irradiation.
469 Penninkhof et al.[84] evaluated the variation in surgical clip position throughout treatment in a cohort
470 of 30 patients treated on the whole-breast with simultaneously integrated boosts using MV,
471 orthogonal kV and CBCT imaging. Clip position was seen to be relatively stable for most patients, with
472 a mean agreement of 1-2mm with the chest wall and external breast contour. A trend towards
473 increased clip displacement was seen over the course of treatment, with three of 30 patients requiring
474 repeat CT and replanning. Significant changes in the seroma can also be detected by 3D imaging earlier
475 in treatment as evidenced by Troung et al.[111], who reported a 13.7% mean reduction in seroma
476 volume between planning CT and first treatment CBCT. Assessment of whole-breast target volumes
477 using CBCT has also shown more than 15% variation in volume over the course of treatment[61]. The
478 information gained by 3D imaging must also be considered alongside its limitations. Increased dose to
479 larger volumes of normal tissue, time of acquisition and limited scan field of view and length are
480 important factors. Additionally, CBCT modalities often bring increased collision risk with the patient,
481 couch, or positioning equipment.

482 SGRT has gained interest over recent years due to its avoidance of ionising radiation and ability to
483 track intrafractional movement. It is a modality well-suited to supine breast position verification as it
484 relies on the external body contour as a surrogate for the treatment volume. Of the seven studies
485 involving SGRT, three involved a comparison with 3D imaging[73,74,78], two with 2D-2D
486 imaging[77,125], and a further two with 2D imaging[75,76]. SGRT has been reported to have a mean
487 agreement within 2mm in all directions of CBCT imaging matched to soft tissue [73,74] or bony
488 anatomy[78]. When evaluated against 2D-2D imaging matched to surgical clips, Gierga et al.[77]
489 reported median residual errors of 3mm and 6mm for gated and free-breathing SGRT, respectively.

490 Chang et al.[79] similarly found mean residual setup errors of approximately 2mm in all directions
491 when comparing surface alignment with clip matching for partial breast irradiation. Of note, SGRT was
492 shown to correlate better with clip location than matching to bony anatomy. SGRT comparisons with
493 2D imaging described good agreement, though neither study reported residual error values[75,76],
494 and the limitations of 2D imaging accuracy must be taken into consideration. An added benefit of
495 SGRT is its ability to be used in real-time to guide patient set-up, and its speed of acquisition and
496 automated assessment compared to other imaging modalities. Ma et al.[78] reported a mean duration
497 of set-up, registration and correction of 1 minute using SGRT compared to 6 minutes with CBCT.

498

499 **Recommendations**

500 From the limited number of studies available, and the small sample sizes observed, only limited
501 guidance on clinical practice can be offered. Larger clinical studies comparing methods of position
502 verification using clearly defined positioning and matching workflows are required in this area. The
503 position verification recommendations from the authors are as follows:

- 504 • Where available, 2D-2D or 3D imaging daily is recommended for online position verification.
- 505 • If 2D-2D or 3D position verification is not available, the limitations of 2D position verification
506 (online or offline) in visualising out-of-plane setup errors should be considered and
507 appropriate target volume margins employed.
- 508 • Image-matching should evaluate bony anatomy directly underlying the treated volume as well
509 as breast tissue or external breast contour.
- 510 • SGRT should not be used as a sole means of position verification without centres first
511 conducting a local study to validate consistent agreement with the pre-existing IGRT modality.
512 Particular caution is advised in the use of SGRT alone for partial-breast or integrated boost
513 treatments, as changes in the surgical bed (or surgical clips as a surrogate) may go undetected.

514 **Considerations**

- 515 • 3D imaging is advantageous for the assessment of soft tissue displacement and change over
516 the course of treatment; however, collision risk must be carefully assessed based on
517 equipment, patient position and isocentre location.
- 518 • The dose contribution from 3D imaging should also be considered, however this is likely to be
519 limited for patients receiving hypofractionated treatment regimes.

520 **Discussion and future work**

521 In this guideline, we described the specific requirements and possibilities in the photon radiation
522 therapy workflow for patients with breast cancer. However, we have not covered some specific items.

523 We did not describe the various techniques for performing Deep Inspiration Breath-hold. This has
524 been thoroughly described in the ESTRO-ACROP guideline: recommendations on implementation of
525 breath-hold techniques in radiotherapy[126]. Furthermore, we did not describe the workflow and
526 necessities of immobilisation and positioning in proton therapy, upright radiotherapy and MR-
527 Linac[127]. These emerging technologies require their own specific considerations, which are beyond
528 the scope of a general guideline.

529

530 Apart from the workflow of patient positioning and position verification in patients with breast cancer
531 one should realise that the choice of a specific treatment technique has certain effects as well. For
532 example, studies have reported conflicting findings regarding IMRT plans as having greater or lesser
533 sensitivity to changes in patient position and contour compared to 3DCRT plans[61,128]. As well as
534 being beyond the scope of the current guideline, the variation and complexity in modern treatment
535 planning approaches requires that departments must have their own internal workflows for
536 evaluating the impact of positioning errors and anatomical changes on delivered dose.

537

538 The image guidance approach adopted should consider the following important factors; a modelling
539 study by Batumalai et al.[129] estimated an increased lifetime attributable risk of developing
540 secondary contralateral breast cancer of between 0.4% and 1.5% from daily MV image guidance.
541 Alvarado et al. obtained the organ doses from the standard low-dose mode CBCT and proposed
542 methods to reduce this dose[130]. Recently Borm et al. found that daily versus weekly CBCT did not
543 affect the target coverage and dose in the organs at risk in VMAT breast cancer radiation treatment
544 [131]. This highlights the important interplay between patient positioning and position verification,
545 whereby positioning workflows with a high level of reproducibility reduce the perceived benefit of
546 higher frequency IGRT. It is however important to note that, particularly in the context of increasingly
547 conformal and complex planning modalities, validation of patient position on a daily basis becomes
548 increasingly important to ensure the accurate delivery of the planned dose.

549

550 In this guideline we included several studies concerning the use of SGRT. However, we did not include
551 the workflow of SGRT in breast positioning. Validation of SGRT as a sole method of set-up and position
552 verification for distinct treatment indications (e.g., whole breast, loco-regional breast cancer, partial-
553 breast) needs to be investigated more thoroughly. In the ESTRO-ACROP SGRT guideline it was
554 recommended that SGRT should be verified by an established x-ray modality of IGRT at least
555 weekly[132].

556

557 Alongside the recommendations and considerations offered within this guideline, it is important to
558 acknowledge the influence of clinical hardware and software on position verification practice. Staff
559 must be appropriately trained in workflows adapted to the locally available technology to ensure IGRT
560 is performed accurately and consistently. While rarely investigated within the literature reviewed,
561 systematic and random interobserver errors of 2mm or larger has been reported across IGRT
562 modalities[100,110]. Hardware limitations can also be a key determinant of position verification
563 workflow due to factors such as collision risk between the gantry and patient or couch top. This is
564 particularly relevant for CBCT workflows, which is anecdotally a frequent challenge reported by
565 departments. Developing this guideline, we noted that there is a future opportunity for a technical
566 guideline on CBCT implementation for breast position verification.

567

568 For researchers studying the field of positioning and set-up accuracy we would recommend
569 considering the following design characteristics at the outset in order that the study findings can be
570 used to inform and improve future radiotherapy practice.

- 571 • In general, low sample sizes made the ability to draw definitive, generalisable conclusions in
572 this guideline impossible. Where possible, researchers should estimate the study sample size
573 using an appropriate power calculation either based on a pilot study or literature where a
574 similar technique has been studied.
- 575 • Where possible new set-up approaches should be tested against the current gold standard
576 using a randomised comparison. Single (non-randomised) cohort design studies do not allow
577 a suitable assessment of accuracy and it becomes difficult to assess whether levels of accuracy
578 achieved are an improvement on existing methods, or whether the magnitude of the benefit
579 obtained with the new set-up method is clinically significant.
- 580 • Possible confounding variables should be measured, reported and included in multi-variate
581 analysis to enable accurate assessment of set-up variations. Confounding variables would
582 include patient BMI, breast volume, whether an immobilisation device was used, or use of a
583 breath-hold technique. Performing these analyses demands larger patient cohorts which may
584 only be met by promoting collaborative multi-centre studies.
- 585 • Within the literature no specific variables have been given to determine which treatment
586 position will be best for each individual patient. Prone could be better for patients with larger
587 breasts. However, the variable “large-breasted” was not described at all or was defined
588 differently in the performed studies. For example, Zhao et al.[20] and Bergom et al.[33]
589 described ml breast volume; Mulliez et al.[14], Buijsen et al.[27] and Kirby et al.[15] used cup
590 size as a unit. For comparing studies, it would be beneficial to use one entity. Ooi et al. found

591 that BMI may be causally linked to larger breast size, but not the reverse, it seems that BMI is
592 a less reliable unit[133]. Therefore, we suggest that breast volume in ml (1ml = 1 cubic
593 centimetre) would be the best unit. Cup size is an inappropriate unit to use as cup size can
594 differ per country or bra manufacturer and each bra cup size covers a large range of breast
595 volumes. For example, women with a breast volume of 1000-1099ml could be fitted to four
596 different Australian bra sizes[134]. Furthermore, Ringberg et al. found that a C-cup size could
597 measure breast volumes with a range of 350ml to 1800ml[135].

- 598 • Thorough documentation of all positioning variables and position verification workflow (e.g.,
599 modality, matching prioritisation) is of importance to ensure any findings can be replicated
600 and applied to practice. This is also required for findings to be combined in reviews or meta-
601 analyses.

602 **Acknowledgments**

603 Thomas Vissers (help with setting up the literature review) and Christa Rooker (help with collecting
604 specific articles), librarians Haaglanden Medical Center, The Hague, NL.

605 Deborah Harrop, librarian Sheffield Hallam University, Sheffield, UK.

606

607 **References**

608

- 609 [1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and
610 mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*
611 2015;136:E359–86. <https://doi.org/10.1002/ijc.29210>.
- 612 [2] Breast Cancer Trialists E, Group C. Effect of radiotherapy after breast-conserving surgery on
613 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data
614 for 10⁸01 women in 17 randomised trials. *The Lancet* 2011;378:1707–16.
615 <https://doi.org/10.1016/S0140>.
- 616 [3] Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK
617 Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for
618 treatment of early breast cancer: 10-year follow-up results of two randomised controlled
619 trials. *Lancet Oncol* 2013;14:1086–94. [https://doi.org/10.1016/S1470-2045\(13\)70386-3](https://doi.org/10.1016/S1470-2045(13)70386-3).
- 620 [4] The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of
621 radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
622 *Lancet* 2008;9:1098–107. <https://doi.org/10.1016/S0140>.
- 623 [5] Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-Term Results of
624 Hypofractionated Radiation Therapy for Breast Cancer. *N Engl J Med* 2010;362:513–20.
625 <https://doi.org/doi:10.1056/NEJMoa0906260>.
- 626 [6] Meattini I, Becherini C, Boersma L, Kaidar-Person O, Marta GN, Montero A, et al. European
627 Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice

- 628 consensus recommendations on patient selection and dose and fractionation for external
629 beam radiotherapy in early breast cancer. *Review Lancet Oncol* 2022;23:21–31.
630 [https://doi.org/doi:10.1016/S1470-2045\(21\)00539-8](https://doi.org/doi:10.1016/S1470-2045(21)00539-8).
- 631 [7] Krug D, Baumann R, Combs SE, Duma MN, Dunst J, Feyer P, et al. Moderate hypofractionation
632 remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations
633 regarding FAST and FAST-Forward. *Strahlentherapie Und Onkologie* 2021;197:269–80.
634 <https://doi.org/10.1007/s00066-020-01744-3>.
- 635 [8] Coles CE, Aristei C, Bliss J, Boersma L, Brunt AM, Chatterjee S, et al. International Guidelines
636 on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. *Clin Oncol*
637 2020;32:279–81. <https://doi.org/10.1016/j.clon.2020.03.006>.
- 638 [9] Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al.
639 Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year
640 efficacy and late normal tissue effects results from a multicentre, non-inferiority,
641 randomised, phase 3 trial. *The Lancet* 2020;395:1613–26. <https://doi.org/doi:10.1200/JCO.19.02750>.
- 643 [10] Murray Brunt A, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-Year
644 Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for
645 Early Breast Cancer. *J Clin Oncol* 2020;38:3261–72. <https://doi.org/doi:10.1200/JCO.19.02750>.
- 647 [11] The FAST Trialists group. First results of the randomised UK FAST Trial of radiotherapy
648 hypofractionation for treatment of early breast cancer (CRUKE/04/015). *Radiotherapy and*
649 *Oncology* 2011;100:93–100. <https://doi.org/10.1016/j.radonc.2011.06.026>.
- 650 [12] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: A
651 tool for assessing risk of bias in non-randomised studies of interventions. *BMJ (Online)*
652 2016;355. <https://doi.org/10.1136/bmj.i4919>.
- 653 [13] Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane
654 Collaboration’s tool for assessing risk of bias in randomised trials. *BMJ (Online)* 2011;343.
655 <https://doi.org/10.1136/bmj.d5928>.
- 656 [14] Mulliez T, Veldeman L, van Greveling A, Speleers B, Sadeghi S, Berwouts D, et al.
657 Hypofractionated whole breast irradiation for patients with large breasts: A randomized trial
658 comparing prone and supine positions. *Radiotherapy and Oncology* 2013;108:203–8.
659 <https://doi.org/10.1016/j.radonc.2013.08.040>.
- 660 [15] Kirby AM, Evans PM, Helyer SJ, Donovan EM, Convery HM, Yarnold JR. A randomised trial of
661 Supine versus Prone breast radiotherapy (SuPr study): Comparing set-up errors and
662 respiratory motion. *Radiotherapy and Oncology* 2011;100:221–6.
663 <https://doi.org/10.1016/j.radonc.2010.11.005>.
- 664 [16] Varga Z, Hideghéty K, Mezo T, Nikolényi A, Thurzó L, Kahán Z. Individual Positioning: A
665 Comparative Study of Adjuvant Breast Radiotherapy in the Prone Versus Supine Position. *Int J*
666 *Radiat Oncol Biol Phys* 2009;75:94–100. <https://doi.org/10.1016/j.ijrobp.2008.10.045>.
- 667 [17] Wang X, Fargier-Bochaton O, Dipasquale G, Laouiti M, Kountouri M, Gorobets O, et al. Is
668 prone free breathing better than supine deep inspiration breath-hold for left whole-breast

- 669 radiotherapy? A dosimetric analysis. *Strahlentherapie Und Onkologie* 2021;197:317–31.
670 <https://doi.org/10.1007/s00066-020-01731-8>.
- 671 [18] Lin H, Liu T, Shi C, Petillion S, Kindts I, Weltens C, et al. Feasibility study of individualized
672 optimal positioning selection for left-sided whole breast radiotherapy: DIBH or prone. *J Appl*
673 *Clin Med Phys* 2018;19:218–29. <https://doi.org/10.1002/acm2.12283>.
- 674 [19] Kahán Z, Rárosi F, Gaál S, Cserháti A, Boda K, Darázs B, et al. A simple clinical method for
675 predicting the benefit of prone vs. supine positioning in reducing heart exposure during left
676 breast radiotherapy. *Radiotherapy and Oncology* 2018;126:487–92.
677 <https://doi.org/10.1016/j.radonc.2017.12.021>.
- 678 [20] Zhao X, Wong EK, Wang Y, Lymberis S, Wen B, Formenti S, et al. A support vector machine
679 (SVM) for predicting preferred treatment position in radiotherapy of patients with breast
680 cancer. *Med Phys* 2010;37:5341–50. <https://doi.org/10.1118/1.3483264>.
- 681 [21] Yu T, Xu M, Sun T, Shao Q, Zhang YJ, Liu XJ, et al. External-beam partial breast irradiation in a
682 supine versus prone position after breast-conserving surgery for Chinese breast cancer
683 patients. *Sci Rep* 2018;8. <https://doi.org/10.1038/s41598-018-33741-z>.
- 684 [22] Krengli M, Masini L, Caltavuturo T, Pisani C, Apicella G, Negri E, et al. Prone versus supine
685 position for adjuvant breast radiotherapy: A prospective study in patients with pendulous
686 breasts. *Radiation Oncology* 2013;8. <https://doi.org/10.1186/1748-717X-8-232>.
- 687 [23] Bartlett FR, Colgan RM, Donovan EM, McNair HA, Carr K, Evans PM, et al. The UK HeartSpare
688 Study (Stage IB): Randomised comparison of a voluntary breath-hold technique and prone
689 radiotherapy after breast conserving surgery. *Radiotherapy and Oncology* 2015;114:66–72.
690 <https://doi.org/10.1016/j.radonc.2014.11.018>.
- 691 [24] Taylor CW, Zhe W, Macaulay E, Jagsi R, Duane F, Darby SC. Exposure of the heart in breast
692 cancer radiation therapy: A systematic review of heart doses published during 2003 to 2013.
693 *Int J Radiat Oncol Biol Phys* 2015;93:845–53. <https://doi.org/10.1016/j.ijrobp.2015.07.2292>.
- 694 [25] Aznar MC, Duane FK, Darby SC, Wang Z, Taylor CW. Exposure of the lungs in breast cancer
695 radiotherapy: A systematic review of lung doses published 2010–2015. *Radiotherapy and*
696 *Oncology* 2018;126:148–54. <https://doi.org/10.1016/j.radonc.2017.11.022>.
- 697 [26] Mitchell J, Formenti SC, DeWyngaert JK. Interfraction and Intrafraction Setup Variability for
698 Prone Breast Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2010;76:1571–7.
699 <https://doi.org/10.1016/j.ijrobp.2009.07.1683>.
- 700 [27] Buijsen J, Jager JJ, Bovendeerd J, Voncken R, Borger JH, Boersma LJ, et al. Prone breast
701 irradiation for pendulous breasts. *Radiotherapy and Oncology* 2007;82:337–40.
702 <https://doi.org/10.1016/j.radonc.2006.08.014>.
- 703 [28] Lai J, Zhong F, Deng J, Hu S, Shen R, Luo H, et al. Prone position versus supine position in
704 postoperative radiotherapy for breast cancer: A meta-analysis. *Medicine* 2021;100:e26000.
705 <https://doi.org/10.1097/MD.0000000000026000>.
- 706 [29] Cardoso JS, Cardoso MJ. Towards an intelligent medical system for the aesthetic evaluation of
707 breast cancer conservative treatment. *Artif Intell Med* 2007;40:115–26.
708 <https://doi.org/10.1016/j.artmed.2007.02.007>.

709 [30] Vakaet V, van Hulle H, Vergotte M, Schoepen M, Deseyne P, van Greveling A, et al. 5-Year
710 Outcomes of a Randomized Trial Comparing Prone and Supine Whole Breast Irradiation in
711 Large-Breasted Women. *Int J Radiat Oncol Biol Phys* 2021;110:766–71.
712 <https://doi.org/10.1016/j.ijrobp.2021.01.026>.

713 [31] Osa EOO, Dewyngaert K, Roses D, Speyer J, Guth A, Axelrod D, et al. Prone breast intensity
714 modulated radiation therapy: 5-year results. *Int J Radiat Oncol Biol Phys* 2014;89:899–906.
715 <https://doi.org/10.1016/j.ijrobp.2014.03.036>.

716 [32] Ann Rose M, Olivotto I, Cady B, Koufman C, Osteen R, Silver B, et al. Conservative Surgery and
717 Radiation Therapy for Early Breast Cancer Long-term Cosmetic Results. 1989.
718 <https://doi.org/doi:10.1001/archsurg.1989.01410020023002>.

719 [33] Bergom C, Kelly T, Morrow N, Wilson JF, Walker A, Xiang Q, et al. Prone whole-breast
720 irradiation using three-dimensional conformal radiotherapy in women undergoing breast
721 conservation for early disease yields high rates of excellent to good cosmetic outcomes in
722 patients with large and/or pendulous breasts. *Int J Radiat Oncol Biol Phys* 2012;83:821–8.
723 <https://doi.org/10.1016/j.ijrobp.2011.08.020>.

724 [34] Huppert N, Jozsef G, DeWyngaert K, Formenti SC. The role of a prone setup in breast
725 radiation therapy. *Front Oncol* 2011;1. <https://doi.org/10.3389/fonc.2011.00031>.

726 [35] Csenki M, Újhidy D, Cserhádi A, Kahán Z, Varga Z. Radiation dose to the nodal regions during
727 prone versus supine breast irradiation. *Ther Clin Risk Manag* 2014;10:367–72.
728 <https://doi.org/10.2147/TCRM.S59483>.

729 [36] Alonso-Basanta M, Ko J, Babcock M, Dewyngaert JK, Formenti SC. Coverage of Axillary Lymph
730 Nodes in Supine vs. Prone Breast Radiotherapy. *Int J Radiat Oncol Biol Phys* 2009;73:745–51.
731 <https://doi.org/10.1016/j.ijrobp.2008.04.040>.

732 [37] Sethi RA, No HS, Jozsef G, Ko JP, Formenti SC. Comparison of three-dimensional versus
733 intensity-modulated radiotherapy techniques to treat breast and axillary level III and
734 supraclavicular nodes in a prone versus supine position. *Radiotherapy and Oncology*
735 2012;102:74–81. <https://doi.org/10.1016/j.radonc.2011.09.008>.

736 [38] Deseyne P, Speleers B, De Neve W, Boute B, Paelinck L, Hoof T Van, et al. Whole breast and
737 regional nodal irradiation in prone versus supine position in left sided breast cancer.
738 *Radiation Oncology* 2017;12. <https://doi.org/10.1186/s13014-017-0828-6>.

739 [39] Speleers BA, Belosi FM, De Gersem WR, Deseyne PR, Paelinck LM, Bolsi A, et al. Comparison
740 of supine or prone crawl photon or proton breast and regional lymph node radiation therapy
741 including the internal mammary chain. *Sci Rep* 2019;9. <https://doi.org/10.1038/s41598-019-41283-1>.

743 [40] Speleers B, Schoepen M, Belosi F, Vakaet V, de Neve W, Deseyne P, et al. Effects of deep
744 inspiration breath hold on prone photon or proton irradiation of breast and regional lymph
745 nodes. *Sci Rep* 2021;11. <https://doi.org/10.1038/s41598-021-85401-4>.

746 [41] Mulliez T, Veldeman L, Speleers B, Mahjoubi K, Remouchamps V, Van Greveling A, et al. Heart
747 dose reduction by prone deep inspiration breath hold in left-sided breast irradiation.
748 *Radiotherapy and Oncology* 2015;114:79–84. <https://doi.org/10.1016/j.radonc.2014.11.038>.

- 749 [42] Boute B, De Neve W, Speleers B, Van Greveling A, Monten C, Van Hoof T V., et al. Potential
750 benefits of crawl position for prone radiation therapy in breast cancer. *J Appl Clin Med Phys*
751 2017;18:200–5. <https://doi.org/10.1002/acm2.12118>.
- 752 [43] Shin SM, No HS, Vega RM, Fenton-Kerimian M, Maisonet O, Hitchen C, et al. Breast, chest
753 wall, and nodal irradiation with prone set-up: Results of a hypofractionated trial with a
754 median follow-up of 35 months. *Pract Radiat Oncol* 2016;6:e81–8.
755 <https://doi.org/10.1016/j.prro.2015.10.022>.
- 756 [44] Campana F, Kirova YM, Rosenwald JC, Dendale R, Vilcoq JR, Dreyfus H, et al. Breast
757 radiotherapy in the lateral decubitus position: A technique to prevent lung and heart
758 irradiation. *Int J Radiat Oncol Biol Phys* 2005;61:1348–54.
759 <https://doi.org/10.1016/j.ijrobp.2004.08.051>.
- 760 [45] Kirova YM, Hijal T, Campana F, Fournier-Bidoz N, Stilhart A, Dendale R, et al. Whole breast
761 radiotherapy in the lateral decubitus position: A dosimetric and clinical solution to decrease
762 the doses to the organs at risk (OAR). *Radiotherapy and Oncology* 2014;110:477–81.
763 <https://doi.org/10.1016/j.radonc.2013.10.038>.
- 764 [46] Bronsart E, Dureau S, Xu HP, Bazire L, Chilles A, Costa E, et al. Whole breast radiotherapy in
765 the lateral isocentric lateral decubitus position: Long-term efficacy and toxicity results.
766 *Radiotherapy and Oncology* 2017;124:214–9. <https://doi.org/10.1016/j.radonc.2017.07.001>.
- 767 [47] Krhili S, Costa E, Xu HP, Kirova YM. Whole breast radiotherapy in the isocentric lateral
768 decubitus position: Role of the immobilization device and table on clinical results.
769 *Cancer/Radiotherapie* 2019;23:209–15. <https://doi.org/10.1016/j.canrad.2018.09.001>.
- 770 [48] Davidson S, Kirsner S, Mason B, Kisling K, Barrett RD, Bonetati A, et al. Dosimetric impact of
771 setup accuracy for an electron breast boost technique. *Pract Radiat Oncol* 2015;5:e499–504.
772 <https://doi.org/10.1016/j.prro.2015.02.011>.
- 773 [49] Haffty BG. Supine or Prone Breast Radiation: Upsides and Downsides. *Int J Radiat Oncol Biol*
774 *Phys* 2018;101:510–2. <https://doi.org/10.1016/j.ijrobp.2018.03.023>.
- 775 [50] Goldsworthy SGS, Sinclair NSN, Tremlett JTJ, Chalmers ACA, Francis MFM, Simcock RSR.
776 Abducting both arms improves stability during breast radiotherapy: The Bi Arm study in
777 radiotherapy. *J Radiother Pract* 2011;10:250–9.
778 <https://doi.org/10.1017/S1460396910000452>.
- 779 [51] Graham P, Elomari F, Brownde L. Armrest versus vacuum bag immobilization in the treatment
780 of breast cancer by radiation therapy: A randomized comparison. *Australas Radiol*
781 2000;44:193–7. <https://doi.org/DOI: 10.1046/j.1440-1673.2000.00804.x>.
- 782 [52] Xiang Q, Jie W, Zhu KK, Wang Q, Cheng J. Which technique of positioning and immobilization
783 is better for breast cancer patients in postmastectomy IMRT, single-pole or double-pole
784 immobilization? *J Appl Clin Med Phys* 2019;20:168–74. <https://doi.org/10.1002/acm2.12506>.
- 785 [53] Saito AI, Vargas C, Morris CG, Lightsey J, Mendenhall NP. Differences between current and
786 historical breast cancer axillary lymph node irradiation based on arm position: Implications
787 for radiation oncologists. *American Journal of Clinical Oncology: Cancer Clinical Trials*
788 2009;32:381–6. <https://doi.org/10.1097/COC.0b013e318191718d>.

- 789 [54] Kapanen M, Laaksomaa M, Skyttä T, Haltamo M, Pehkonen J, Lehtonen T, et al. Residual
790 position errors of lymph node surrogates in breast cancer adjuvant radiotherapy: Comparison
791 of two arm fixation devices and the effect of arm position correction. *Medical Dosimetry*
792 2016;41:47–52. <https://doi.org/10.1016/j.meddos.2015.08.001>.
- 793 [55] Lauridsen MC, Christiansen P, Hesselø I. The effect of physiotherapy on shoulder function in
794 patients surgically treated for breast cancer: A randomized study. *Acta Oncol (Madr)*
795 2005;44:449–57. <https://doi.org/10.1080/02841860510029905>.
- 796 [56] Leal NFB da S, de Oliveira HF, Carrara HHA. Fisioterapia supervisionada nas mulheres em
797 radioterapia para o câncer de mama. *Rev Lat Am Enfermagem* 2016;24.
798 <https://doi.org/10.1590/1518-8345.0702.2755>.
- 799 [57] Yang A, Sokolof J, Gulati A. The effect of preoperative exercise on upper extremity recovery
800 following breast cancer surgery: A systematic review. *International Journal of Rehabilitation*
801 *Research* 2018;41:189–96. <https://doi.org/10.1097/MRR.000000000000288>.
- 802 [58] Brahmbhatt P, Sabiston CM, Lopez C, Chang E, Goodman J, Jones J, et al. Feasibility of
803 Prehabilitation Prior to Breast Cancer Surgery: A Mixed-Methods Study. *Front Oncol* 2020;10.
804 <https://doi.org/10.3389/fonc.2020.571091>.
- 805 [59] Wu F, Laza-Cagigas R, Pagarkar A, Olaoke A, el Gammal M, Rampal T. The Feasibility of
806 Prehabilitation as Part of the Breast Cancer Treatment Pathway. *PM and R* 2021;13:1237–46.
807 <https://doi.org/10.1002/pmrj.12543>.
- 808 [60] Roos J, Mast M, Egmond van E, Petoukhova A, Struikmans H. Van wig naar plat: wat is het
809 effect op de dosis in het normale weefsel bij borstsparende bestraling. *Gamma Professional*
810 2013;63:22–5.
- 811 [61] Jain P, Marchant T, Green M, Watkins G, Davies J, McCarthy C, et al. Inter-fraction motion and
812 dosimetric consequences during breast intensity-modulated radiotherapy (IMRT).
813 *Radiotherapy and Oncology* 2009;90:93–8. <https://doi.org/10.1016/j.radonc.2008.10.010>.
- 814 [62] Arenas M, Hernández V, Farrús B, Müller K, Gascón M, Pardo A, et al. Do breast cups improve
815 breast cancer dosimetry? A comparative study for patients with large or pendulous breasts.
816 *Acta Oncol (Madr)* 2014;53:795–801. <https://doi.org/10.3109/0284186X.2014.893062>.
- 817 [63] Shi L, He C, Guo X, Zhao L, Fu T, Han B. Original Article A new method to deliver breast and
818 chest wall radiation in breast radiotherapy for lung and heart sparing. *Int J Clin Exp Med*
819 2016;9:13484–92.
- 820 [64] Kelly A, Hardcastle N, Metcalfe P, Cutajar D, Quinn A, Foo K, et al. Surface dosimetry for
821 breast radiotherapy in the presence of immobilization cast material. *Phys Med Biol*
822 2011;56:1001–13. <https://doi.org/10.1088/0031-9155/56/4/008>.
- 823 [65] Agostinelli S, Garelli S, Bellini A, Pupillo F, Guenzi M, Bosetti D, et al. Helical Tomotherapy of
824 the breast: Can thermoplastic immobilization improve the reproducibility of the treatment
825 setup and the accuracy of the delivered dose? *Physica Medica* 2015;31:49–53.
826 <https://doi.org/10.1016/j.ejmp.2014.09.007>.
- 827 [66] Kawamura M, Maeda Y, Yamamoto K, Takamatsu S, Sato Y, Minami H, et al. Development of
828 the breast immobilization system in prone setup: The effect of bra in prone position to

- 829 improve the breast setup error. *J Appl Clin Med Phys* 2017;18:155–60.
830 <https://doi.org/10.1002/acm2.12116>.
- 831 [67] Arimura T, Ogino T, Yoshiura T, Matsuyama M, Kondo N, Miyazaki H, et al. A feasibility study
832 of a hybrid breast-immobilization system for early breast cancer in proton beam therapy:
833 *Med Phys* 2017;44:1268–74. <https://doi.org/10.1002/mp.12166>.
- 834 [68] Snider JW, Mutaf Y, Nichols E, Hall A, Vadnais P, Regine WF, et al. Dosimetric Improvements
835 with a Novel Breast Stereotactic Radiotherapy Device for Delivery of Preoperative Partial-
836 Breast Irradiation. *Oncology (Switzerland)* 2017;92:21–30.
837 <https://doi.org/10.1159/000449388>.
- 838 [69] Probst H, Dodwell D, Gray JC, Holmes M. An evaluation of the accuracy of semi-permanent
839 skin marks for breast cancer irradiation. *Radiography* 2006;12:186–8.
840 <https://doi.org/10.1016/j.radi.2005.07.001>.
- 841 [70] Probst H, Rosbottom K, Crank H, Stanton A, Reed H. The patient experience of radiotherapy
842 for breast cancer: A qualitative investigation as part of the SuPPORT 4 All study. *Radiography*
843 2021;27:352–9. <https://doi.org/10.1016/j.radi.2020.09.011>.
- 844 [71] Petillion S, Verhoeven K, Weltens C, van den Heuvel F. Efficacy and workload analysis of a
845 fixed vertical couch position technique and a fixed-action-level protocol in whole-breast
846 radiotherapy. *J Appl Clin Med Phys* 2015;16. <https://doi.org/doi:10.1120/jacmp.v16i2.5265>.
- 847 [72] González-Sanchis A, Brualla-González L, Fuster-Diana C, Gordo-Partearroyo JC, Piñeiro-Vidal
848 T, García-Hernandez T, et al. Surface-guided radiation therapy for breast cancer: more precise
849 positioning. *Clinical and Translational Oncology* 2021;23:2120–6.
850 <https://doi.org/10.1007/s12094-021-02617-6>.
- 851 [73] Wei X, Liu M, Ding Y, Li Q, Cheng C, Zong X, et al. Setup errors and effectiveness of Optical
852 Laser 3D Surface imaging system (Sentinel) in postoperative radiotherapy of breast cancer.
853 *Sci Rep* 2018;8. <https://doi.org/10.1038/s41598-018-25644-w>.
- 854 [74] Cravo Sá A, Fermento A, Neves D, Ferreira S, Silva T, Marques Coelho C, et al. Radiotherapy
855 setup displacements in breast cancer patients: 3D surface imaging experience. *Reports of*
856 *Practical Oncology and Radiotherapy* 2018;23:61–7.
857 <https://doi.org/10.1016/j.rpor.2017.12.007>.
- 858 [75] Li S, de Weese T, Movsas B, Frassica D, Liu D, Kim J, et al. Initial Validation and Clinical
859 Experience with 3D Optical-Surface-Guided Whole Breast Irradiation of Breast Cancer.
860 *Technol Cancer Res Treat* 2012;11:57–68. <https://doi.org/doi:10.7785/tcrt.2012.500235>.
- 861 [76] Deantonio L, Masini L, Loi G, Gambaro G, Bolchini C, Krengli M. Detection of setup
862 uncertainties with 3D surface registration system for conformal radiotherapy of breast
863 cancer. *Reports of Practical Oncology and Radiotherapy* 2011;16:77–81.
864 <https://doi.org/10.1016/j.rpor.2011.02.003>.
- 865 [77] Gierga DP, Riboldi M, Turcotte JC, Sharp GC, Jiang SB, Taghian AG, et al. Comparison of Target
866 Registration Errors for Multiple Image-Guided Techniques in Accelerated Partial Breast
867 Irradiation. *Int J Radiat Oncol Biol Phys* 2008;70:1239–46.
868 <https://doi.org/10.1016/j.ijrobp.2007.11.020>.

- 869 [78] Ma Z, Zhang W, Su Y, Liu P, Pan Y, Zhang G, et al. Optical Surface Management System for
870 Patient Positioning in Interfractional Breast Cancer Radiotherapy. *Biomed Res Int* 2018;2018.
871 <https://doi.org/10.1155/2018/6415497>.
- 872 [79] Chang AJ, Zhao H, Wahab SH, Moore K, Taylor M, Zoberi I, et al. Video surface image
873 guidance for external beam partial breast irradiation. *Pract Radiat Oncol* 2012;2:97–105.
874 <https://doi.org/10.1016/j.prro.2011.06.013>.
- 875 [80] Feng CH, Gerry E, Chmura SJ, Hasan Y, Al-Hallaq HA. An image-guided study of setup
876 reproducibility of postmastectomy breast cancer patients treated with inverse-planned
877 intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2015;91:58–64.
878 <https://doi.org/10.1016/j.ijrobp.2014.09.007>.
- 879 [81] Thomsen MS, Harrov U, Fledelius W, Poulsen PR. Inter- and intra-fraction geometric errors in
880 daily image-guided radiotherapy of free-breathing breast cancer patients measured with
881 continuous portal imaging. *Acta Oncol (Madr)* 2014;53:802–8.
882 <https://doi.org/10.3109/0284186X.2014.905700>.
- 883 [82] Topolnjak R, Sonke JJ, Nijkamp J, Rasch C, Minkema D, Remeijer P, et al. Breast patient setup
884 error assessment: Comparison of electronic portal image devices and cone-beam computed
885 tomography matching results. *Int J Radiat Oncol Biol Phys* 2010;78:1235–43.
886 <https://doi.org/10.1016/j.ijrobp.2009.12.021>.
- 887 [83] Fatunase T, Wang Z, Yoo S, Hubbs JL, Prosnitz RG, Yin FF, et al. Assessment of the Residual
888 Error in Soft Tissue Setup in Patients Undergoing Partial Breast Irradiation: Results of a
889 Prospective Study Using Cone-Beam Computed Tomography. *Int J Radiat Oncol Biol Phys*
890 2008;70:1025–34. <https://doi.org/10.1016/j.ijrobp.2007.07.2344>.
- 891 [84] Penninkhof J, Quint S, Boer H de, Mens JW, Heijmen B, Dirks M. Surgical clips for position
892 verification and correction of non-rigid breast tissue in simultaneously integrated boost (SIB)
893 treatments. *Radiotherapy and Oncology* 2009;90:110–5.
894 <https://doi.org/10.1016/j.radonc.2008.10.009>.
- 895 [85] Miyahara Kanae, Kuroda Masahiro, Yoshimura Yuuki, Aoyama Hideki, Oita Masataka,
896 Sugianto Irfan, et al. Evaluation of Setup Errors at the Skin Surface Position for Whole Breast
897 Radiotherapy of Breast Cancer Patients. *Acta Medica Okayamag* 2018:331–6.
898 <https://doi.org/doi:10.18926/AMO/56167>.
- 899 [86] Jensen CA, Roa AMA, Johansen M, Lund JÅ, Frengen J. Robustness of VMAT and 3DCRT plans
900 toward setup errors in radiation therapy of locally advanced left-sided breast cancer with
901 DIBH. *Physica Medica* 2018;45:198–204. <https://doi.org/10.1016/j.ejmp.2017.11.019>.
- 902 [87] Jones S, Fitzgerald R, Owen R, Ramsay J. Quantifying intra- and inter-fractional motion in
903 breast radiotherapy. *J Med Radiat Sci* 2015;62:40–6. <https://doi.org/10.1002/jmrs.61>.
- 904 [88] Lutz CM, Poulsen PR, Fledelius W, Offersen BV, Thomsen MS. Setup error and motion during
905 deep inspiration breath-hold breast radiotherapy measured with continuous portal imaging.
906 *Acta Oncol (Madr)* 2016;55:193–200. <https://doi.org/10.3109/0284186X.2015.1045625>.
- 907 [89] Yue NJ, Goyal S, Kim LH, Khan A, Haffty BG. Patterns of intrafractional motion and
908 uncertainties of treatment setup reference systems in accelerated partial breast irradiation
909 for right- and left-sided breast cancer. *Pract Radiat Oncol* 2014;4:6–12.
910 <https://doi.org/10.1016/j.prro.2012.12.003>.

- 911 [90] Yang DS, Yoon WS, Chung SY, Lee JA, Lee S, Park YJ, et al. Set-up uncertainty during breast
912 radiotherapy: Image-guided radiotherapy for patients with initial extensive variation.
913 *Strahlentherapie Und Onkologie* 2013;189:315–20. <https://doi.org/10.1007/s00066-012-0271-4>.
914
- 915 [91] Kinoshita R, Shimizu S, Taguchi H, Katoh N, Fujino M, Onimaru R, et al. Three-Dimensional
916 Intrafractional Motion of Breast During Tangential Breast Irradiation Monitored With High-
917 Sampling Frequency Using a Real-Time Tumor-Tracking Radiotherapy System. *Int J Radiat
918 Oncol Biol Phys* 2008;70:931–4. <https://doi.org/10.1016/j.ijrobp.2007.10.003>.
- 919 [92] Morrow N v., Stepaniak C, White J, Wilson JF, Li XA. Intra- and Interfractional Variations for
920 Prone Breast Irradiation: An Indication for Image-Guided Radiotherapy. *Int J Radiat Oncol Biol
921 Phys* 2007;69:910–7. <https://doi.org/10.1016/j.ijrobp.2007.06.056>.
- 922 [93] Koseoglu FG, Tuncel N, Kizildag AU, Garipagaoglu M, Adli M, Andic C. Assessment of setup
923 accuracy in patients receiving postmastectomy radiotherapy using electronic portal imaging.
924 *Radiation Medicine - Medical Imaging and Radiation Oncology* 2007;25:45–52.
925 <https://doi.org/10.1007/s11604-006-0102-6>.
- 926 [94] Mukundan H, Mukherjee D, Tyagi K, Taneja S, Ranjan S, Sahu S. Dosimetric and isocentric
927 variations due to patient setup errors in CT-based treatment planning for breast cancer by
928 electronic portal imaging. *Med J Armed Forces India* 2020;76:51–7.
929 <https://doi.org/10.1016/j.mjafi.2018.07.008>.
- 930 [95] Murthy K, Al-Rahbi Z, Sivakumar S, Davis C, Ravichandran R, el Ghamrawy K. Verification of
931 setup errors in external beam radiation therapy using electronic portal imaging. *J Med Phys*
932 2008;33:49–53. <https://doi.org/10.4103/0971-6203.41192>.
- 933 [96] Jacob J, Heymann S, Borget I, Dumas I, Riahi E, Maroun P, et al. Dosimetric effects of the
934 interfraction variations during whole breast radiotherapy: A prospective study. *Front Oncol*
935 2015;5. <https://doi.org/10.3389/fonc.2015.00199>.
- 936 [97] Hwang JM, Hung JY, Tseng YH, Chang YK, Wang YN, Chang CS. Use of electronic portal images
937 to evaluate setup error and intra-fraction motion during free-breathing breast IMRT
938 treatment. *Medical Dosimetry* 2019;44:233–8.
939 <https://doi.org/10.1016/j.meddos.2018.08.001>.
- 940 [98] Hirata K, Yoshimura M, Mukumoto N, Nakamura M, Inoue M, Sasaki M, et al. Three-
941 dimensional intrafractional internal target motions in accelerated partial breast irradiation
942 using three-dimensional conformal external beam radiotherapy. *Radiotherapy and Oncology*
943 2017;124:118–23. <https://doi.org/10.1016/j.radonc.2017.04.023>.
- 944 [99] Strom EA, Amos RA, Shaitelman SF, Kerr MD, Hoffman KE, Smith BD, et al. Proton partial
945 breast irradiation in the supine position: Treatment description and reproducibility of a
946 multibeam technique. *Pract Radiat Oncol* 2015;5:e283–90.
947 <https://doi.org/10.1016/j.prro.2015.01.010>.
- 948 [100] Laaksomaa M, Kapanen M, Skyttä T, Peltola S, Hyödynmaa S, Kellokumpu-Lehtinen PL.
949 Estimation of optimal matching position for orthogonal kV setup images and minimal setup
950 margins in radiotherapy of whole breast and lymph node areas. *Reports of Practical Oncology
951 and Radiotherapy* 2014;19:369–75. <https://doi.org/10.1016/j.rpor.2014.05.001>.

- 952 [101] Harris EJ, Donovan EM, Coles CE, de Boer HCJ, Poynter A, Rawlings C, et al. How does imaging
953 frequency and soft tissue motion affect the PTV margin size in partial breast and boost
954 radiotherapy? *Radiotherapy and Oncology* 2012;103:166–71.
955 <https://doi.org/10.1016/j.radonc.2012.03.015>.
- 956 [102] Park CK, Pritz J, Zhang GG, Forster KM, Harris EER. Validating fiducial markers for image-
957 guided radiation therapy for accelerated partial breast irradiation in early-stage breast
958 cancer. *Int J Radiat Oncol Biol Phys* 2012;82. <https://doi.org/10.1016/j.ijrobp.2011.07.027>.
- 959 [103] Lozano EM, Pérez LA, Torres J, Carrascosa C, Sanz M, Mendicote F, et al. Correction of
960 systematic set-up error in breast and head and neck irradiation through a no-action level
961 (NAL) protocol. *Clinical and Translational Oncology*, vol. 13, 2011, p. 34–42.
962 <https://doi.org/10.1007/s12094-011-0614-0>.
- 963 [104] Yue NJ, Goyal S, Zhou J, Khan AJ, Haffty BG. Intrafractional target motions and uncertainties
964 of treatment setup reference systems in accelerated partial breast irradiation. *Int J Radiat
965 Oncol Biol Phys* 2011;79:1549–56. <https://doi.org/10.1016/j.ijrobp.2010.05.034>.
- 966 [105] Lawson JD, Fox T, Elder E, Nowlan A, Davis L, Keller J, et al. Early Clinical Experience With
967 Kilovoltage Image-Guided Radiation Therapy for Interfraction Motion Management. *Medical
968 Dosimetry* 2008;33:268–74. <https://doi.org/10.1016/j.meddos.2007.06.002>.
- 969 [106] Semaniak A, Kukołowicz P. Set-up uncertainty during postmastectomy radiotherapy with
970 Segmented Photon Beams Technique. *Reports of Practical Oncology and Radiotherapy*
971 2015;20:181–7. <https://doi.org/10.1016/j.rpor.2015.01.009>.
- 972 [107] Petillion S, Verhoeven K, Weltens C, van den Heuvel F. Accuracy of a new paired imaging
973 technique for position correction in whole breast radiotherapy. *J Appl Clin Med Phys*
974 2015;16:22–31. <https://doi.org/doi:10.1120/jacmp.v16i1.4796>.
- 975 [108] Chung MJ, Lee GJ, Suh YJ, Lee HC, Lee SW, Jeong S, et al. Setup error and effectiveness of
976 weekly image-guided radiation therapy of tomotherapy for early breast cancer. *Cancer Res
977 Treat* 2015;47:774–80. <https://doi.org/10.4143/crt.2014.189>.
- 978 [109] van Mourik A, van Kranen S, den Hollander S, Sonke JJ, van Herk M, van Vliet-Vroegindewij
979 C. Effects of setup errors and shape changes on breast radiotherapy. *Int J Radiat Oncol Biol
980 Phys* 2011;79:1557–64. <https://doi.org/10.1016/j.ijrobp.2010.07.032>.
- 981 [110] White EA, Cho J, Vallis KA, Sharpe MB, Lee G, Blackburn H, et al. Cone Beam Computed
982 Tomography Guidance for Setup of Patients Receiving Accelerated Partial Breast Irradiation.
983 *Int J Radiat Oncol Biol Phys* 2007;68:547–54. <https://doi.org/10.1016/j.ijrobp.2007.01.048>.
- 984 [111] Truong MT, Hirsch AE, Kovalchuk N, Qureshi MM, Damato A, Schuller B, et al. Cone-beam
985 computed tomography image guided therapy to evaluate lumpectomy cavity variation before
986 and during breast radiotherapy. *J Appl Clin Med Phys* 2013;14. <https://doi.org/doi:10.1120/jacmp.v14i2.4243>.
- 987
- 988 [112] Jung JH, Cho KH, Moon SK, Bae SH, Min CK, Kim ES, et al. Rotation Errors of Breast Cancer on
989 3D-CRT in TomoDirect. *Progress in Medical Physics* 2015;26:6.
990 <https://doi.org/10.14316/pmp.2015.26.1.6>.
- 991 [113] Hasan Y, Kim L, Wloch J, Chi Y, Liang J, Martinez A, et al. Comparison of planned versus actual
992 dose delivered for external beam accelerated partial breast irradiation using cone-beam CT

- 993 and deformable registration. *Int J Radiat Oncol Biol Phys* 2011;80:1473–6.
 994 <https://doi.org/10.1016/j.ijrobp.2010.04.013>.
- 995 [114] Jung JH, Jung JY, Bae SH, Moon SK, Cho KH. Setup deviations for whole-breast radiotherapy
 996 with TomoDirect: A comparison of weekly and biweekly image-guided protocols. *Journal of*
 997 *the Korean Physical Society* 2016;69:1247–53. <https://doi.org/10.3938/jkps.69.1247>.
- 998 [115] Alderliesten T, Heemsbergen WD, Betgen A, Topolnjak R, Elkhuizen PHM, van Vliet-
 999 Vroegindewei C, et al. Breast-shape changes during radiation therapy after breast-conserving
 1000 surgery. *Phys Imaging Radiat Oncol* 2018;6:71–6.
 1001 <https://doi.org/10.1016/j.phro.2018.05.006>.
- 1002 [116] Sánchez-Rubio P, Rodríguez-Romero R, Castro-Tejero P. A retrospective tomotherapy image-
 1003 guidance study: Analysis of more than 9,000 MVCT scans for ten different tumor sites. *J Appl*
 1004 *Clin Med Phys* 2014;15:30–45. <https://doi.org/10.1120/jacmp.v15i6.4663>.
- 1005 [117] Barbés B, Azcona JD, Prieto E, de Foronda JM, García M, Burguete J. Development and clinical
 1006 evaluation of a simple optical method to detect and measure patient external motion. *J Appl*
 1007 *Clin Med Phys* 2015;16:306–21. <https://doi.org/10.1120/jacmp.v16i5.5524>.
- 1008 [118] Acharya S, Fischer-Valuck BW, Mazur TR, Curcuru A, Sona K, Kashani R, et al. Magnetic
 1009 Resonance Image Guided Radiation Therapy for External Beam Accelerated Partial-Breast
 1010 Irradiation: Evaluation of Delivered Dose and Intrafractional Cavity Motion. *Int J Radiat Oncol*
 1011 *Biol Phys* 2016;96:785–92. <https://doi.org/10.1016/j.ijrobp.2016.08.006>.
- 1012 [119] van Heijst TCF, Philippens MEP, Charaghvandi RK, den Hartogh MD, Legendijk JJW, Desirée
 1013 Van Den Bongard HJG, et al. Quantification of intra-fraction motion in breast radiotherapy
 1014 using supine magnetic resonance imaging. *Phys Med Biol* 2016;61:1352–70.
 1015 <https://doi.org/10.1088/0031-9155/61/3/1352>.
- 1016 [120] Zhang R, Andreozzi JM, Gladstone DJ, Hitchcock WL, Glaser AK, Jiang S, et al. Cherenkovscopy
 1017 based patient positioning validation and movement tracking during post-lumpectomy whole
 1018 breast radiation therapy. *Phys Med Biol* 2015;60:L1–14. [https://doi.org/10.1088/0031-](https://doi.org/10.1088/0031-9155/60/1/L1)
 1019 [9155/60/1/L1](https://doi.org/10.1088/0031-9155/60/1/L1).
- 1020 [121] Chadha M, Young A, Geraghty C, Masino R, Harrison L. Image guidance using 3D-ultrasound
 1021 (3D-US) for daily positioning of lumpectomy cavity for boost irradiation. *Radiation Oncology*
 1022 2011;6. <https://doi.org/10.1186/1748-717X-6-45>.
- 1023 [122] de Boer HCJ, And MS, Heijmen BJM. A protocol for the reduction of systematic patient setup
 1024 errors with minimal portal imaging workload. *Int J Radiat Oncol Biol Phys* 2001;50:1350–65.
 1025 [https://doi.org/doi:10.1016/s0360-3016\(01\)01624-8](https://doi.org/doi:10.1016/s0360-3016(01)01624-8).
- 1026 [123] de Boer HCJ, Heijmen BJM. eNAL: An Extension of the NAL Setup Correction Protocol for
 1027 Effective Use of Weekly Follow-up Measurements. *Int J Radiat Oncol Biol Phys* 2007;67:1586–
 1028 95. <https://doi.org/10.1016/j.ijrobp.2006.11.050>.
- 1029 [124] van Herk M. Errors and Margins in Radiotherapy. *Semin Radiat Oncol* 2004;14:52–64.
 1030 <https://doi.org/10.1053/j.semradonc.2003.10.003>.
- 1031 [125] Chang AJ, Zhao H, Wahab SH, Moore K, Taylor M, Zoberi I, et al. Video surface image
 1032 guidance for external beam partial breast irradiation. *Pract Radiat Oncol* 2012;2:97–105.
 1033 <https://doi.org/10.1016/j.prro.2011.06.013>.

- 1034 [126] Aznar MC, Carrasco de fez P, Corradini S, Mast M, McNair H, Meattini I, et al. ESTRO-ACROP
1035 guideline: Recommendations on implementation of breath-hold techniques in radiotherapy.
1036 Radiotherapy and Oncology 2023;185. <https://doi.org/10.1016/j.radonc.2023.109734>.
- 1037 [127] Cuccia F, Alongi F, Belka C, Boldrini L, Hörner-Rieber J, McNair H, et al. Patient positioning and
1038 immobilization procedures for hybrid MR-Linac systems. Radiation Oncology 2021;16.
1039 <https://doi.org/10.1186/s13014-021-01910-6>.
- 1040 [128] Fung WWK, Wu VWC. Image-guided radiation therapy using computed tomography in
1041 radiotherapy. J Radiother Pract 2011;10:121–36.
1042 <https://doi.org/10.1017/S1460396910000270>.
- 1043 [129] Batumalai V, Quinn A, Jameson M, Delaney G, Holloway L. Imaging dose in breast
1044 radiotherapy: Does breast size affect the dose to the organs at risk and the risk of secondary
1045 cancer to the contralateral breast? J Med Radiat Sci 2015;62:32–9.
1046 <https://doi.org/10.1002/jmrs.91>.
- 1047 [130] Alvarado R, Booth JT, Bromley RM, Gustafsson HB. An investigation of image guidance dose
1048 for breast radiotherapy. J Appl Clin Med Phys 2013;14:25–38.
1049 <https://doi.org/10.1120/jacmp.v14i3.4085>.
- 1050 [131] Borm KJ, Junker Y, Düsberg M, Devečka M, Münch S, Dapper H, et al. Impact of CBCT
1051 frequency on target coverage and dose to the organs at risk in adjuvant breast cancer
1052 radiotherapy. Sci Rep 2021;11. <https://doi.org/10.1038/s41598-021-96836-0>.
- 1053 [132] Freislederer P, Batista V, Öllers M, Buschmann M, Steiner E, Kügele M, et al. ESTRO-ACROP
1054 guideline on surface guided radiation therapy. Radiotherapy and Oncology 2022;173:188–96.
1055 <https://doi.org/10.1016/j.radonc.2022.05.026>.
- 1056 [133] Ooi BNS, Loh H, Ho PJ, Milne RL, Giles G, Gao C, et al. The genetic interplay between body
1057 mass index, breast size and breast cancer risk: A Mendelian randomization analysis. Int J
1058 Epidemiol 2019;48:781–94. <https://doi.org/10.1093/ije/dyz124>.
- 1059 [134] McGhee DE, Steele JR. Breast volume and bra size. International Journal of Clothing Science
1060 and Technology 2011;23:351–60.
1061 <https://doi.org/https://doi.org/10.1108/09556221111166284>.
- 1062 [135] Ringberg A, Bågeman E, Rose C, Ingvar C, Jernström H. Of cup and bra size: Reply to a
1063 prospective study of breast size and premenopausal breast cancer incidence [1]. Int J Cancer
1064 2006;119:2242–3. <https://doi.org/10.1002/ijc.22104>.
- 1065